IkB alpha/NFKBIA Protein, Human, Recombinant (His) NEW
| Price | $600 |
| Package | 50μg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-01 |
Product Details
| Product Name: IkB alpha/NFKBIA Protein, Human, Recombinant (His) | Purity: > 90 % as determined by SDS-PAGE |
| Supply Ability: 10g | Release date: 2025/05/01 |
Product Introduction
Bioactivity
| Name | IkB alpha/NFKBIA Protein, Human, Recombinant (His) |
| Description | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IkB alpha, NFKBIA, or IKBA), is a member of the NF-kappa-B inhibitor family that function to inhibit the NF-kB transcription factor. NFKBIA inhibits NF-kB by masking the nuclear localization signals (NLS) of NF-kB proteins and keeping them sequestered in an inactive state in the cytoplasm. Also, NFKBIA blocks the ability of NF-κB transcription factors to bind to DNA, which is required for NF-kB's proper functioning. Signal-induced degradation of I kappa B alpha exposes the nuclear localization signal of NF-kappa B, thus allowing it to translocate into the nucleus and activate transcription from responsive genes. An autoregulatory loop is established when NF-kappa B induces expression of the I kappa B alpha gene and newly synthesized I kappa B alpha accumulates in the nucleus where it negatively regulates NF-kappa B-dependent transcription. As part of this post-induction repression, the nuclear export signal on I kappa B alpha mediates the transport of NF-kappa B-I kappa B alpha complexes from the nucleus to the cytoplasm. Deletion of NFKBIA has an effect that is similar to the effect of EGFR amplification in the pathogenesis of glioblastoma and is associated with comparatively short survival. Polymorphisms in NFKBIA may be important in pre-disposition to and outcome after treatment, of multiple myeloma (MM). The NFKBIA gene product, IkappaBalpha, binds to NF-kappaB preventing its activation and is important in mediating resistance to apoptosis in B-cell lymphoproliferative diseases. |
| Storage | Shipping with blue ice. |
| Keywords | MAD3 | MAD 3 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $583.00/200μg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-08-27 | |
| $2530.00/1mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $101.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2023-12-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY